These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35211673)

  • 21. Lilly Research Award Program (LRAP): A Successful Academia-Industry Partnership Model in the Context of Flow Chemistry for Drug Discovery.
    Mateos C
    Chimia (Aarau); 2019 Oct; 73(10):803-808. PubMed ID: 31645240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.
    Hammonds T
    Future Med Chem; 2015; 7(14):1891-9. PubMed ID: 26393391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sugammadex: a review of its use in anaesthetic practice.
    Yang LP; Keam SJ
    Drugs; 2009; 69(7):919-42. PubMed ID: 19441874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of neuromuscular blockade with sugammadex during continuous administration of anaesthetic agents: a double-blind randomised crossover study using the bispectral index.
    Le Guen M; Roussel C; Chazot T; Dumont GA; Liu N; Fischler M
    Anaesthesia; 2020 May; 75(5):583-590. PubMed ID: 31808151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma.
    McElroy SP; Jones PS; Barrault DV
    Drug Discov Today; 2017 Feb; 22(2):199-203. PubMed ID: 27720829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges.
    Mundy C; Bush J; Cheriyan J; Lorch U; Stringer S; Taubel J; Wydenbach K; Hardman TC
    Front Pharmacol; 2023; 14():1219591. PubMed ID: 38026971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open for collaboration: an academic platform for drug discovery and development at SciLifeLab.
    Arvidsson PI; Sandberg K; Forsberg-Nilsson K
    Drug Discov Today; 2016 Oct; 21(10):1690-1698. PubMed ID: 27373760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Consideration on Academia Environments for Creating Medical Innovation].
    Iida K; Ishida T; Nishimura N
    Yakugaku Zasshi; 2022 Jan; 142(1):75-84. PubMed ID: 34629350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings.
    Bash LD; Turzhitsky V; Black W; Urman RD
    Adv Ther; 2021 Sep; 38(9):4736-4755. PubMed ID: 34319550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial.
    Baysal A; Sagıroglu G; Dogukan M; Ozkaynak I
    J Perianesth Nurs; 2022 Jun; 37(3):326-332. PubMed ID: 35153119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-operative urinary retention is impacted by neuromuscular block reversal agent choice: A retrospective cohort study in US hospital setting.
    Bash LD; Turzhitsky V; Mark RJ; Hofer IS; Weingarten TN
    J Clin Anesth; 2024 May; 93():111344. PubMed ID: 38007845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
    Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
    J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategy of Daiichi Sankyo discovery research in oncology.
    Akahane K; Hirokawa K
    Jpn J Clin Oncol; 2014 Feb; 44(2):109-15. PubMed ID: 24459194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
    Wong EH; Yocca F; Smith MA; Lee CM
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.